Yu Du - Concepedia

Author

Yu Du

Eli Lilly (United States)ORCID

Also Known As

Du, Yu, Y. Du, YU DU, Yong Du, Yu Du, Yu Zheng Du, Yu zheng Du, Yu-Zheng Du, Yu-zheng Du, Yuzheng Du

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Velocity Clinical Research (United States)Harvard University Yale University

About

Yu Du is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	673
2	Pharmacology	3	3	532
3	Diabetes	2	2	507
4	Biostatistics	1	1	141
5	Psychiatry	1	1	25

Yu Du

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, New England Journal of Medicine	2023	830
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff, The Lancet Glucagon Receptor AgonistDiabetes ManagementMedicineDiabetesType 2	2023	327
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Tamer Coşkun, Shweta Urva, William C. Roell, Cell Metabolism	2022	246
Development of a Claims-based Frailty Indicator Anchored to a Well-established Frailty Phenotype Jodi B Segal, Hsien‐Yen Chang, Yu Du, Medical Care	2017	229
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Arun J. Sanyal, Lee M. Kaplan, Juan P. Frías, Nature Medicine	2024	186
Efficacy of Intensive Acupuncture Versus Sham Acupuncture in Knee Osteoarthritis: A Randomized Controlled Trial Jian‐Feng Tu, Jing‐Wen Yang, Guang‐Xia Shi, Arthritis & Rheumatology	2020	183
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Shweta Urva, Tamer Coşkun, Mei Teng Loh, The Lancet Glucagon Receptor AgonistG Protein-coupled ReceptorMedicineDiabetesType 2	2022	180
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data Justin Guinney, Tao Wang, Teemu D. Laajala, The Lancet Oncology Prognostic BiomarkersUrologyMedicinePredictive AnalyticsPrognosis	2016	141
Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist Olivier Bénichou, Tamer Coşkun, Malgorzata D. Gonciarz, Cell Metabolism	2023	87
ATR-FTIR combined with machine learning for the fast non-targeted screening of new psychoactive substances Yu Du, Zhendong Hua, Cuimei Liu, Forensic Science International Substance AbusePre-clinical PharmacologyHit IdentificationMachine LearningPsychiatry	2023	25

Page 1